ASTRO: Cisplatin with RT and HDRB beneficial for cervical cancer

Share this article:
ASTRO: Cisplatin Plus RT, HDRB Beneficial for Cervical Cancer
ASTRO: Cisplatin Plus RT, HDRB Beneficial for Cervical Cancer

(HealthDay News) -- For women with stage IIIB squamous cervical cancer, cisplatin added to radiotherapy plus high-dose-rate brachytherapy (HDRB) is associated with improved disease-free survival, according to a study presented at the annual meeting of the American Society for Therapeutic Radiation Oncology, held from Sept. 22 to 25 in Atlanta.

Antonio C. Zuliani, M.D., from Campinas State University in Brazil, and colleagues conducted a randomized clinical trial to compare disease-free and overall survival of 147 women with stage IIIB squamous cervical cancer randomized to receive cisplatin plus radiotherapy (CHRT; 72 women) or radiotherapy alone (RT; 75 women). Radiotherapy comprised external-beam radiation to the pelvic region in 25 fractions, 14.4 Gy boost to compromised parametria, and HDRB.

The researchers found that women in the CHRT group had significantly better disease-free survival (hazard ratio, 0.52). Overall survival was better in the CHRT group, but the difference was not statistically significant (hazard ratio, 0.67; P = 0.16). Grades 1 and 2 acute toxicity were not significantly different between the groups (P = 0.29), nor were late toxicity grades 3 and 4 (P = 0.29).

"We believe that these results demonstrate that this combined treatment protocol is safe to offer to patients and provides some beneficial improvements -- in disease-free survival and toxicity levels," Zuliani said in a statement.

Press Release
More Information

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.